A reappraisal of oophorectomy in carcinoma of the breast

Ann Surg. 1987 Jan;205(1):18-21. doi: 10.1097/00000658-198701000-00004.

Abstract

Bilateral oophorectomy was used to treat 601 patients with disseminated breast carcinoma from 1974-1984. The total response rate was 31.2%. Complete regression occurred in 10.5% of patients and partial regression occurred in 20.8%, whereas 28.3% of patients showed no change and the disease progressed in 36.9% of patients. The patients who had a total regression had good survival rates (60.8% at 5 years and 47.3% at 7 years). No significant differences were found in the various age groups or with different types of dissemination. Patients with syncronous primary carcinoma and distant metastases had a high rate of regression as did patients with slow-growing carcinomas that metastasized many years after primary treatment. Estrogen receptor (ER) rates were good indicators of response only when determined on metastatic tissue at the time of oophorectomy. The value of ER determined on the primary tumor was of limited predictivity of response. A total of 220 patients received chemotherapy before oophorectomy. In this group the response rate was 22.3%, lower than that observed in patients who did not receive chemotherapy (36.6%). No important differences in total response rates were found among patients with amenorrhea and without amenorrhea although total regressions were more frequent in the latter patients than in the former patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / mortality
  • Breast Neoplasms / therapy*
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Evaluation Studies as Topic
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Methotrexate / therapeutic use
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local / analysis
  • Ovariectomy*
  • Prognosis
  • Receptors, Estrogen / analysis
  • Time Factors

Substances

  • Receptors, Estrogen
  • Cisplatin
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF protocol